By Ambar Bhattacharyya

Congratulations to Rachel Haurwitz, Jennifer Doudna, and the entire Caribou (NASDAQ: CRBU) team on today’s public debut! This incredible milestone marks the pinnacle of a decade of scientific innovation and next-generation technology.

Founded by pioneers in CRISPR genome editing, Caribou has fueled the development of next-generation immune cell therapies for the treatment of cancer. For nearly a decade, the company has developed proprietary technology to build a pipeline of wholly-owned allogeneic immune cell therapies for oncology. CB-010, Caribou’s leading program, is an anti-CD19 CAR-T that is currently in a phase 1 trial in B-cell non-Hodgkin lymphoma.


Maverick Ventures

As the venture capital arm of Maverick Capital, we partner with entrepreneurs in the healthcare, software & technology sectors. More at

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store